HERCULES, Calif.--(BUSINESS WIRE)--
A Federal District Court jury yesterday found that 10X Genomics willfully infringed three United States patents owned by the University of Chicago and exclusively licensed to Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products (NYSE:BIO and BIOb). In awarding Bio-Rad $23.9 million in damages, the jury unanimously found that all Single Cell and Linked-Read genomics products sold by 10X Genomics willfully infringed the patents owned by the University of Chicago and licensed to Bio-Rad.
“We are obviously pleased with the outcome of the case,” said Norman Schwartz, Bio-Rad President and Chief Executive Officer. “Bio-Rad remains committed to growing and protecting its portfolio of patents in the droplet microfluidics space and to delivering differentiated genomics technologies that enable world class research.”
In a separate earlier action before the International Trade Commission, an administrative law judge made an initial determination that certain microfluidic devices used by 10X in its products infringe patent rights owned by Bio-Rad.
Bio-Rad Laboratories, Inc. (NYSE:BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.1 billion in 2017. For more information, please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding Bio-Rad remaining committed to growing and protecting its portfolio of patents in the droplet microfluidics space and to delivering differentiated genomics technologies that enable world class research. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “commit”, “will,” “expect,” “anticipate,” “plan,” “intend,” “estimate,” “believe,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to intellectual property rights, international legal and regulatory risks, our ability to develop and market new or improved products, our ability to compete effectively, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.